Optimal length of triple therapy for H pylori eradication in a population with high prevalence of infection in Chile

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 21

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

316

HTML

2133

Figures (1-1)

277

Tables (1-3)

205

Sum=2931

Jun 7, 2007 (publication date) through Feb 3, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Rapid Communication

World J Gastroenterol. Jun 7, 2007; 13(21): 2967-2972
Published online Jun 7, 2007. doi: 10.3748/wjg.v13.i21.2967

Table 2 Eradication rate after treatment and subgroup analyses n (%)

Eradication rate according to:	OAC7(n = 69)	OAC14(n = 62)	P
Length of treatment	54 (78.3)	53 (85.5)	0.37
Smoking status
Smoker	8 (57.1)	17 (81)	0.15
Non smoker	46 (83.6)	36 (87.8)	0.88
Endoscopic diagnosis
Ulcer disease	12 (85.7)	21 (87.5)	1.0
Non-ulcer disease	35 (79.5)	25 (83.3)	0.77
Normal	7 (63.6)	7 (87.5)	0.34
Previous antibiotic exposure
Betalactamics	46 (82.1)	43 (84.3)	0.8
Clarithromycin	10 (76.9)	16 (88.9)	0.63
Metronidazol	9 (69.2)	10 (83.3)	0.64
Tetracycline	25 (78.1)	20 (76.9)	1.0

Citation: Riquelme A, Soza A, Pedreros C, Bustamante A, Valenzuela F, Otarola F, Abbott E, Arellano M, Medina B, Pattillo A, Greig D, Arrese M, Rollan A. Optimal length of triple therapy for H pylori eradication in a population with high prevalence of infection in Chile. World J Gastroenterol 2007; 13(21): 2967-2972
URL: https://www.wjgnet.com/1007-9327/full/v13/i21/2967.htm
DOI: https://dx.doi.org/10.3748/wjg.v13.i21.2967